[Clinical value of ethinyl estradiol sulfonate (Turisteron)--long-term results of a randomized compound study].
In a randomized compound study the therapy effect of ethinylestradiol sulfonate (Turisteron) is tested. As comparative groups serve patients with chemotherapy and Turisteron in combination with chemotherapy. The cumulative 5-year survival rate under the therapy of Turisteron was 61.2%. The comparative groups do not achieve this high survival rate. In connection with the slight stress of the patients (application form, side effects) ethinylestradiol sulfonate (Turisteron) is an effective estrogen in the long-term treatment of the advanced carcinoma of the prostate gland.
D000368:Aged; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004997:Ethinyl Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011897:Random Allocation
C025723:ethinyl estradiol sulfonate; D004997:Ethinyl Estradiol
Zum klinischen Wert von Athinylöstradiolsulfonat (Turisteron)--Langzeitergebnisse einer randomisierten Verbundstudie.